Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...
Pfizer Launches Migraine Management Zone at China Pharmacy
Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...
Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors
Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion
Innovent Biologics, Inc. (HKG: 1801) reported strong financial results for Q4 and full‑year 2025, with total...
Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study
Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...
Takeda Ends $128M Kyoto University iPSC Project After Decade of Research
Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...
Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care
China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...
AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter
AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....
AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025
AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...
Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System
Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...
Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development
Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...
Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...
Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...
Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...
Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
Bio-Thera Solutions (SHA: 688177) announced a licensing agreement with Avalon Pharma, granting the Saudi Arabia‑headquartered...
Marubeni Launches Xenleta in China After Complex Licensing Journey
Marubeni Pharmaceuticals (China) Co., Ltd. (formerly Sumitomo Pharma China) announced the initiation of commercialization for...
CMS-D017 Gets NMPA Approval for Complement-Mediated Kidney Disease Study
China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA) has...
Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China
Akeso Biopharma (HKG: 9926) announced a partnership with Jumpcan Pharmaceutical (SHA: 600566) granting Jumpcan exclusive...
United Laboratories UBT251 Gets NMPA Nod for Sleep Apnea Trial
United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products Administration (NMPA) has...
Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...